Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma

Inclusion Criteria: * Males and females patients, aged \>3 years and \< 30 years; * Newly diagnosed of GBM, DIPG, diffuse brainstem glioma, diffuse spinal glioma, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma; * Patients undergone either surgery or biopsy only; * No prior chemotherapy and/or radiotherapy; * Life expectancy ≥ 4 weeks; * Karnofsky/Lansky ≥ 40 %; * Written informed consent obtained from the patient/parents or legal representative; * Adequate hematological function (leucocyte ≥ 2.0 x 10\^9/l -Hemoglobin ≥ 10 g/dl - platelet ≥ 50 x 10\^9 /l); * Adequate liver function (total bilirubin ≤ 2.5 x ULN - ALT/AST ≤ 5.0 x ULN); * Adequate renal function (serum creatinine ≤ 1.5 x ULN); * Adherence to trial treatment and compliance with the protocol Exclusion Criteria: * Any disease or condition that contraindicates the use of the study drug (es. serious mental retardation, brain palsy, congenital syndrome, cardiomyopathy) * Prior anti-cancer therapy * Pregnancy or breastfeeding * Non adequate contraception